{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:00:51Z","timestamp":1767135651959,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010828","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T00:00:00Z","timestamp":1412035200000}}],"reference-count":83,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010828.pub2","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T11:10:13Z","timestamp":1412075413000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Azapirones versus placebo for panic disorder in adults"],"prefix":"10.1002","volume":"2014","author":[{"given":"Hissei","family":"Imai","sequence":"first","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Field Medicine; Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aran","family":"Tajika","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyao","family":"Chen","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pompoli","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico G.B. Rossi Piazzale L.A. Scuro 10 Verona Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Western University; Department of Psychiatry; Saint Thomas Elgin General Hospital 189 Elm Street St Thomas ON Canada N5R 5C4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariasole","family":"Castellazzi","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico G.B. Rossi Piazzale L.A. Scuro 10 Verona Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico G.B. Rossi Piazzale L.A. Scuro 10 Verona Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Girlanda","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico G.B. Rossi Piazzale L.A. Scuro 10 Verona Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico G.B. Rossi Piazzale L.A. Scuro 10 Verona Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Koesters","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany D-89312"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,30]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD010828.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000284627","article-title":"Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone","volume":"22","author":"Pohl","year":"1989","journal-title":"Psychopathology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0002|cit2","first-page":"21","article-title":"Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone","volume":"25","author":"Robinson","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0091-3057(88)90214-6","article-title":"The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report","volume":"29","author":"Sheehan","year":"1988","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199002000-00002","article-title":"Is buspirone effective for panic disorder?","volume":"10","author":"Sheehan","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1993.tb03405.x","article-title":"The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study","volume":"88","author":"Sheehan","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD010828.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1097\/00004714-199006001-00010","article-title":"Buspirone therapy in anxious elderly patients: a controlled clinical trial","volume":"10","author":"Bohm","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD010828.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1097\/00004714-199006001-00008","article-title":"A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting","volume":"10","author":"Bohm","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000289102","article-title":"Study and course of the psychological profile in 77 patients experiencing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone","volume":"66","author":"Bouvard","year":"1997","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0893-133X(02)00298-1","article-title":"Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder","volume":"27","author":"Broocks","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0924-977X(02)00177-3","article-title":"5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo","volume":"13","author":"Broocks","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0011|cit11","first-page":"97","volume":"37","author":"Bueno","year":"1988","journal-title":"Journal Brasileiro de Psiquiatria"},{"issue":"5","key":"10.1002\/14651858.CD010828.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1192\/bjp.167.5.635","article-title":"A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia","volume":"167","author":"Cottraux","year":"1995","journal-title":"British Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010828.pub2-BIB0013|cit13","first-page":"95","article-title":"Drug interactions in controlled clinical trials","volume":"43","author":"Gershon","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0014|cit14","first-page":"90","article-title":"Buspirone - a new antianxiety agent not chemically related to any presently marketed drugs","volume":"15","author":"Goldberg","year":"1979","journal-title":"Psychopharmacology Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD010828.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1176\/ajp.136.9.1184","article-title":"The comparative efficacy of buspirone and diazepam in the treatment of anxiety","volume":"136","author":"Goldberg","year":"1979","journal-title":"American Journal of Psychiatry"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD010828.pub2-BIB0016|cit16","first-page":"87","article-title":"Comparison of buspirone in two separate studies","volume":"12","author":"Goldberg","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0017|cit17","first-page":"219","article-title":"Ipsapirone: evidence for efficacy in depression","volume":"26","author":"Heller","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD010828.pub2-BIB0018|cit18","first-page":"277","article-title":"A clinical comparative trial of buspirone in the treatment of anxiety neurosis","volume":"20","author":"Hongbo","year":"1994","journal-title":"Chinese Journal of Nervous and Mental Disease"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0019|cit19","first-page":"85","article-title":"A comparative study in psychotherapy and drug in teatment of anxiety disorders","volume":"28","author":"Hua","year":"1994","journal-title":"Chinese Journal of Nervous and Mental Disorder"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010828.pub2-BIB0020|cit20","first-page":"5398","article-title":"Pharmaco-EEG studies on buspirone, a new anxiolytic drug, in high- and low-anxious humans","volume":"15","author":"Kai","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD010828.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-1781(02)00250-0","article-title":"Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression","volume":"113","author":"Klaassen","year":"2002","journal-title":"Psychiatry Research"},{"issue":"8","key":"10.1002\/14651858.CD010828.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1526-4610.2005.05181.x","article-title":"Eficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study","volume":"45","author":"Lee","year":"2005","journal-title":"Headache"},{"issue":"18","key":"10.1002\/14651858.CD010828.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0024-3205(90)90359-Y","article-title":"Subsensitivity of the 5-hydroxytryptamine1A (5-HT1A) receptor-mediated hypothermic response to ipsapirone in unipolar depression","volume":"46","author":"Lesch","year":"1990","journal-title":"Life Science"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02253597","article-title":"5-HT1A receptor-effector system responsivity in panic disorder","volume":"106","author":"Lesch","year":"1992","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0025|cit25","first-page":"117","article-title":"Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine","volume":"47","author":"Mavissakalian","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0026|cit26","first-page":"447","article-title":"Clinical study of buspirone on neurosis - a comparative double-blind trial with placebo","volume":"19","author":"Miura","year":"1992","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0027|cit27","first-page":"259","article-title":"Late phase III study of a new anxiolytic SM-3997 (tandospirone) on neurosis","volume":"20","author":"Murasaki","year":"1992","journal-title":"Clinical Evaluation"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD010828.pub2-BIB0028|cit28","first-page":"100","article-title":"The side effect profile of buspirone in comparison to active controls and placebo","volume":"43","author":"Newton","year":"1982","journal-title":"journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00007611-199002000-00014","article-title":"Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety","volume":"83","author":"Rakel","year":"1990","journal-title":"Southern Medical Journal"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(87)90196-3","article-title":"Assessing the efficacy of antianxiety agents","volume":"82","author":"Rakel","year":"1987","journal-title":"The American Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010828.pub2-BIB0031|cit31","first-page":"40","article-title":"Recent advances in anxiolytic therapy","volume":"42","author":"Rickels","year":"1981","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010828.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","article-title":"Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy","volume":"157","author":"Rickels","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/cap.1994.4.159","article-title":"Buspirone therapy of mixed anxiety disorders in childhood and adolescence: a pilot study","volume":"4","author":"Simeon","year":"1994","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0022-3956(84)90048-7","article-title":"Anxiety in primary care: is short-term drug treatment appropriate?","volume":"18","author":"Tyrer","year":"1984","journal-title":"Journal of Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0035|cit35","first-page":"86","article-title":"Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients","volume":"12","author":"Laar","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0036|cit36","first-page":"112","article-title":"Buspirone (Buspar), a double-blind comparative study of two dosing schedules","volume":"15","author":"Zelvelder","year":"1990","journal-title":"Journal for Drug Therapy and Research"},{"issue":"7","key":"10.1002\/14651858.CD010828.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"7066","key":"10.1002\/14651858.CD010828.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness for summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0039|cit39","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0040|cit40","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423905.154688","article-title":"American Psychiatric Association Practice Guidelines for the Treatment of Panic Disorder","volume-title":"American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder","author":"American Psychiatric Association","year":"2009"},{"issue":"6","key":"10.1002\/14651858.CD010828.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1017\/S1461145711000800","article-title":"Evidence-based pharmacotherapy of panic disorder: an update","volume":"15","author":"Batelaan","year":"2011","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0043|cit43","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"12","key":"10.1002\/14651858.CD010828.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s001270050098","article-title":"Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS)","volume":"33","author":"Bijl","year":"1998","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0045|cit45","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [in French]","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"8","key":"10.1002\/14651858.CD010828.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.160.8.1432","article-title":"Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?","volume":"160","author":"Bruce","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1345\/aph.1D267","article-title":"Industry sponsorship and authorship of clinical trials over 20 years","volume":"38","author":"Buchkowsky","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006115","article-title":"Azapirones for generalized anxiety disorder","author":"Chessick","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educational and Psychological Measurement"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0050|cit50","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa"},{"issue":"5","key":"10.1002\/14651858.CD010828.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/npp.2010.246","article-title":"Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral\/basolateral amygdala","volume":"36","author":"Diaz","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.151.3.413","article-title":"Panic and panic disorder in the United States","volume":"151","author":"Eaton","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004364.pub2","article-title":"Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia","author":"Furukawa","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD010828.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/ajp.152.10.1438","article-title":"DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis","volume":"152","author":"Goisman","year":"1995","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.v67n0305","article-title":"The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Grant","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD010828.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676","article-title":"Antidepressants versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD010828.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0063|cit63","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","article-title":"The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication","volume":"63","author":"Kessler","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010828.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.bp.107.039966","article-title":"Prevalence of common mental disorders in general practice attendees across Europe","volume":"192","author":"King","year":"2008","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010828.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1017\/S1461145713000151","article-title":"Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis","volume":"16","author":"Kishi","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02193476","article-title":"Delineation of two drug-responsive anxiety syndromes","volume":"5","author":"Klein","year":"1964","journal-title":"Psychopharmacologia"},{"issue":"7400","key":"10.1002\/14651858.CD010828.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"British Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD010828.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/S0007125000296232","article-title":"Buspirone: a worldwide update","volume":"159(Suppl 12)","author":"Napoliello","year":"1991","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"193","author":"Nash","year":"2008","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010828.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1523\/JNEUROSCI.4921-03.2004","article-title":"Reduced serotonin type 1A receptor binding in panic disorder","volume":"24","author":"Neumeister","year":"2004","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0073|cit73","volume-title":"Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults [CG113]","author":"National Institute for Health and Clinical Excellence","year":"2011"},{"issue":"18","key":"10.1002\/14651858.CD010828.pub2-BIB0074|cit74","first-page":"10734-9","article-title":"Increased anxiety of mice lacking the serotonin1A receptor","volume":"95","author":"Parks","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0075|cit75","unstructured":"Payer D Bolleau I Guranda M Graff A Nakajima S Meyer J Buspirone occupancy of D2\/3 dopamine receptors in humans measured by positron emission tomography Proceedings of the College on Problems of Drug Dependence, 75th Annual Scientific Meeting, San Diego, CA"},{"issue":"2","key":"10.1002\/14651858.CD010828.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011004","article-title":"Psychological therapies for panic disorder with or without agoraphobia in adults","author":"Pompoli","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010828.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0091-3057(88)90214-6","article-title":"The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report","volume":"29","author":"Sheehan","year":"1988","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199002000-00002","article-title":"Is buspirone effective for panic disorder?","volume":"10","author":"Sheehan","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0079|cit79","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195369250.001.0001","volume-title":"Anxiety Disorders in Adults: A Clinical Guide","author":"Starcevic","year":"2009"},{"key":"10.1002\/14651858.CD010828.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/7854_2009_35","article-title":"Pharmacologic treatment of panic disorder","volume":"2","author":"Stein","year":"2010","journal-title":"Current Topics in Behavioral Neurosciences"},{"issue":"8","key":"10.1002\/14651858.CD010828.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1176\/appi.ajp.158.8.1326","article-title":"Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers","volume":"158","author":"Tauscher","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010828.pub2-BIB0082|cit82","first-page":"13","article-title":"Antidepressants in panic disorder","volume":"14","author":"Wade","year":"1999","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010828.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005335.pub2","article-title":"Combined psychotherapy plus benzodiazepines for panic disorder","author":"Watanabe","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010828.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T06:34:29Z","timestamp":1697956469000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010828.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,30]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010828.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,30]]}}}